VJHemOnc is committed to improving our service to you

IMW 2019 | WM: BTK inhibitors

VJHemOnc is committed to improving our service to you

Jorge Castillo and Ramon Garcia-Sanz

From the International Myeloma Workshop (IMW) 2019, held in Boston, MA, Jorge Castillo, MD, from Dana-Farber Cancer Institute, Boston, MA, and Ramon Garcia-Sanz, MD, from University Hospital of Salamanca, Salamanca, Spain, discuss the exciting new agents for the treatment of Waldenström’s Macroglobulinemia (WM) that are emerging from current clinical trials. This discussion highlights venetoclax, ibrutinib and newer BTK (Bruton tyrosine kinase) inhibitors such as acalabrutinib and zanubrutinib.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter